Claritev Corporation (CTEV) is a publicly traded Healthcare sector company. As of May 21, 2026, CTEV trades at $21.18 with a market cap of $279.92M and a P/E ratio of -1.19. CTEV moved +31.67% today. Year to date, CTEV is -28.07%; over the trailing twelve months it is -26.04%. Its 52-week range spans $11.50 to $74.07. Analyst consensus is strong buy with an average price target of $32.00. Rallies surfaces CTEV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Claritev’s Shares Plunge 40.9% Near 52-Week Low After PHCS Novera Launch: Claritev Corporation’s stock tumbled 40.9% to trade near its 52-week low after unveiling its PHCS Novera primary network solution designed for healthcare cost management. The sharp decline positioned Claritev as the day’s worst performer despite broader sector volatility.
| Metric | Value |
|---|---|
| Price | $21.18 |
| Market Cap | $279.92M |
| P/E Ratio | -1.19 |
| EPS | $-17.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $74.07 |
| 52-Week Low | $11.50 |
| Volume | 81 |
| Avg Volume | 0 |
| Revenue (TTM) | $965.41M |
| Net Income | $-284.28M |
| Gross Margin | 0.00% |
4 analysts cover CTEV: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.00.